Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
The stream of new year layoffs that have greeted biotech employees shows no sign of abating, with Exelixis announcing that around 175 of its staff will be heading for the exits in the coming months.